Molecular Epidemiology of Dioxin-Related Illness in Seveso

NCT ID: NCT00340873

Last Updated: 2020-04-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

1994-12-12

Study Completion Date

2020-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 1976 an accidental explosion in a chemical plant 16 miles north of Milan resulted in contamination of the local population with 2, 3, 7, 8-terachlorodibenzo-para-dioxin (TCDD). There is evidence that TCDD and related phenoxy herbicides act as teratogens, tumor promoters, and carcinogens in experimental animals. In human, TCDD causes chloracne in those exposed. Associations with various cancers have been reported, but the precise role in human toxicity, immune and reproductive dysfunction, and cancer is controversial.

The Seveso accident provides a unique opportunity for an epidemiological investigation in that the exposures are the highest recorded in humans, the exposure involves TCDD without other contaminants, and a cohort in the involved and surrounding area has been enumerated.

There is inter-individual variation in the action of genes involved in TCDD effect in human cells. The quality of human AH receptor, and the CYP1A1 and arnt genotypes are examples of susceptibility markers that may identify subjects at high risk for TCDD-related disease. A hypothesis that could explain the inconsistent association of TCDD exposure with cancer is that genetic susceptibility may influence which individuals are adversely affected by TCDD exposure.

The study is proceeding in three phases. The first is a pilot/validation study that is complete (field activities) and involved 126 subjects. The second is a case-control study of about 100 individuals with chloracne and 100 controls. The field components of phase one and two are complete, and analyses of results are underway. The third and final phase is a planned case-control study of TCDD-related cancers that will include approximately 125 cases and 125 controls.

The study includes a questionnaire/interview and a biospecimen collection; 73 ml of blood are obtained from each participant.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 1976 an accidental explosion in a chemical plant 16 miles north of Milan resulted in contamination of the local population with 2, 3, 7, 8-tetrachlorodibenzo-para-dioxin (TCDD). There is evidence that TCDD and related phenoxy herbicides act as teratogens, tumor promoters, and carcinogens in experimental animals. In human, TCDD causes chloracne in those exposed. Associations with various cancers have been reported, but the precise role in human toxicity, immune and reproductive dysfunction, and cancer is controversial.

The Seveso accident provides a unique opportunity for an epidemiological investigation in that the exposures are the highest recorded in humans, the exposure involves TCDD without other contaminants, and a cohort in the involved and surrounding area has been enumerated.

There is inter-individual variation in the action of genes involved in TCDD effect in human cells. The quality of human AH receptor, and the CYP1A1 and arnt genotypes are examples of susceptibility markers that may identify subjects at high risk for TCDD-related disease. A hypothesis that could explain the inconsistent association of TCDD exposure with cancer is that genetic susceptibility may influence which individuals are adversely affected by TCDD exposure.

The study is in three phases. The first is a pilot/validation study of 126 highly exposed and not exposed subjects. The second is a case-control study of 100 individuals with chloracne and 100 controls. The field components of phase one and two are complete. The third and final phase is a planned case-control study of TCDD-related cancers that will include approximately 125 cases and 125 controls.

Using different methods to estimate TCDD levels below the detection limit, we found that, approximately 20 years after the accident, plasma TCDD was still elevated in subjects from the exposed areas, particularly in women, and was negatively associated with IgG plasma levels. Subjects who developed chloracne after the accident had high TCDD levels, and no evidence of TCDD-related long-term toxicity.

The analyses of the expression of key genes in the aryl hydrocarbon receptor (AhR) pathway, which is necessary for most TCDD effects, showed a significant reduction in AhR expression by increasing plasma dioxin levels. Cytochrome P450 gene SNPs and haplotypes were associated with variable TCDD-related gene inducibility.

On-going studies are examining the proteomics and gene expression pattern (by microarray) in exposed subjects compared with not exposed individuals, and the frerquency of t(14;18) translocations in lymphocytes from the same subjects.

The study includes a questionnaire/interview and a biospecimen collection; 73 ml of blood were obtained from each participant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

2,3,7,8-Tetrachlorodibenzo-Para-Dioxin (TCDD) Exposure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Individuals exposed to digoxin

No interventions assigned to this group

Controls

Individuals not exposed to digoxin

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects exposed to TCDD in the region of Lombardy, Italy.

Exclusion Criteria

1. severe medical illness: liver (cirrhosis \[based on medical history\], chronic or acute hepatitis \[based on transaminase elevation, SGOT greater than 200 IU or SGPT greater than 200 IU\]), kidney (hemo- or peritoneal dialysis dependent), cardiac (myocardial infarct in the last 6 months), AIDS (or known HIV positive), major psychiatric illness (decompensated schizophrenia);
2. IV drug abuse;
3. individuals receiving a few specific medications known to interfere with specific assays (i.e., phenobarbitol), other medication use will be recorded;
4. non-Italian origin;
5. Any condition which precludes obtaining informed consent.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria T Landi, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute (NCI)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Milan

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Baccarelli A, Giacomini SM, Corbetta C, Landi MT, Bonzini M, Consonni D, Grillo P, Patterson DG, Pesatori AC, Bertazzi PA. Neonatal thyroid function in Seveso 25 years after maternal exposure to dioxin. PLoS Med. 2008 Jul 29;5(7):e161. doi: 10.1371/journal.pmed.0050161.

Reference Type BACKGROUND
PMID: 18666825 (View on PubMed)

Consonni D, Sindaco R, Agnello L, Caporaso NE, Landi MT, Pesatori AC, Bertazzi PA. Plasma levels of dioxins, furans, non-ortho-PCBs, and TEQs in the Seveso population 17 years after the accident. Med Lav. 2012 Jul-Aug;103(4):259-67.

Reference Type BACKGROUND
PMID: 22880488 (View on PubMed)

McHale CM, Zhang L, Hubbard AE, Zhao X, Baccarelli A, Pesatori AC, Smith MT, Landi MT. Microarray analysis of gene expression in peripheral blood mononuclear cells from dioxin-exposed human subjects. Toxicology. 2007 Jan 5;229(1-2):101-13. doi: 10.1016/j.tox.2006.10.004. Epub 2006 Oct 17.

Reference Type BACKGROUND
PMID: 17101203 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OH95-C-N038

Identifier Type: -

Identifier Source: secondary_id

999995038

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Functional Implications of TNF
NCT00729131 COMPLETED
Bisphenol A Controlled Exposure Study
NCT01573429 COMPLETED PHASE1